February 21, 2026

#clinical trial — Saturday, February 21, 2026 (3 items)

hot top new

ℹ	Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. (linkinghub.elsevier.com)	Noureddin M … Loomba R The Lancet 2026-02-21	#clinical trial #therapeutics #fibrosis #steatohepatitis
ℹ	Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial. (linkinghub.elsevier.com)	Xiong Y … Wang Y The Lancet 2026-02-21	#clinical trial #stroke #thrombectomy #thrombolysis
ℹ	Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (linkinghub.elsevier.com)	Broderick JP … Grotta JC The Lancet 2026-02-21	#clinical trial #stroke #hemorrhage #coagulation #hemostasis